GlycoNex receives PMDA approval in Japan to initiate first-in-human phase 1 trial of GNX1021 in gastrointestinal cancers

CAR-T Digest - August 2020

14 April 2026: GlycoNex receives PMDA approval in Japan to initiate first-in-human phase 1 trial of GNX1021 in gastrointestinal cancers

GlycoNex, Inc. has received approval from Japan’s Pharmaceuticals and Medical Devices Agency to initiate a first-in-human Phase 1 clinical trial of its lead antibody-drug conjugate GNX1021 in patients with advanced gastrointestinal cancers
Supported by favorable preclinical safety data and a strong biological rationale, GNX1021 has the potential to offer a new therapeutic approach for difficult-to-treat gastrointestinal cancers and may attract significant strategic interest as it advances in clinical development
The Phase 1 study is a multicenter, multinational trial that will evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy, while also determining the recommended dose for subsequent clinical development
GNX1021 utilizes a differentiated mechanism by targeting aberrant glycan structures such as the bLeB/Y antigen expressed across multiple tumor-associated proteins, enabling broader tumor targeting with high specificity and minimal expression in normal tissues
This milestone marks the company’s transition into clinical-stage development for its glycan-targeting ADC platform, highlighting a novel approach designed to address tumor heterogeneity across gastrointestinal malignancies